FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806769033> ?p ?o ?g. }

• W2806769033 endingPage "123" @default.
• W2806769033 startingPage "106" @default.
• W2806769033 abstract "Novel Insights into Pathophysiology, Diagnostics and Treatment of Myelodysplastic Syndromes Hematopoietic stem cell transplantation in patients with myelodysplastic syndromesGuido KobbeGuido KobbeGuido Kobbe is Professor of Medicine and Specialist for hematopoietic stem cell transplant medicine in patients with hematological malignances. He is Head of the Adult Stem Cell Transplant Program at the University Hospital Düsseldorf (Germany). His special interest lies in the improvement of clinical transplant programs as well as in the early detection and successful therapy of relapse after hematopoietic stem cell transplantation.Search for more papers by this authorPublished Online:2 Jan 2014https://doi.org/10.2217/fmeb2013.13.94AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: Hematopoietic insufficiency is the cause of most of the clinical symptoms in patients with myelodysplastic syndromes (MDS) and is responsible for almost all disease-related deaths, especially by bleeding and infection. In addition, during the course of the disease, advanced MDS often transforms into acute myeloid leukemia. MDS incidence is 2–5 per 100,000 per year, but increases with age. In Germany, the incidence among a population of individuals over the age of 65 years is approximately 30 per 100,000 per year. The mean age at diagnosis is approximately 75 years [1]. References1 Germing U , Strupp C , Kundgen A et al. No increase in age-specific incidence of myelodysplastic syndromes . Haematologica 89 , 905 – 910 (2004) . Medline, Google Scholar2 Garcia-Manero G . Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management . Am. J. Hematol. 86 , 490 – 498 (2011) . Crossref, Medline, CAS, Google Scholar3 Gattermann N . How to treat MDS without stem cell transplantation . Biol. Blood Marrow Transplant. 16 , S30 – S36 (2010) . Crossref, Medline, Google Scholar4 Appelbaum FR . Hematopoietic-cell transplantation at 50 . N. Engl. J. Med. 357 , 1472 – 1475 (2007) . Crossref, Medline, CAS, Google Scholar5 Germing U , Hildebrandt B , Pfeilstocker M et al. Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) . Leukemia 19 , 2223 – 2231 (2005) . Crossref, Medline, CAS, Google Scholar6 Malcovati L , Germing U , Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes . J. Clin. Oncol. 25 , 3503 – 3510 (2007) . Crossref, Medline, Google Scholar7 Kuendgen A , Strupp C , Aivado M et al. Myelodysplastic syndromes in patients younger than age 50 . J. Clin. Oncol. 24 , 5358 – 5365 (2006) . Crossref, Medline, Google Scholar8 Cutler C . Patient selection for transplantation in the myelodysplastic syndromes . Hematol. Oncol. Clin. North Am. 24 , 469 – 476 (2010) . Crossref, Medline, Google Scholar9 Kindwall-Keller T , Isola LM . The evolution of hematopoietic SCT in myelodysplastic syndrome . Bone Marrow Transplant. 43 , 597 – 609 (2009) . Crossref, Medline, CAS, Google Scholar10 Kroger N , Brand R , van BA et al. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes . Bone Marrow Transplant. 35 , 37 – 43 (2005) . Crossref, Medline, CAS, Google Scholar11 De Witte T , Hagemeijer A , Suciu S et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial . Haematologica 95 , 1754 – 1761 (2010) . Crossref, Medline, CAS, Google Scholar12 Kroger N , Zabelina T , de Wreede L et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings . Leukemia 27 (3) , 604 – 609 (2013) . Crossref, Medline, CAS, Google Scholar13 Guardiola P , Runde V , Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes . Blood 99 , 4370 – 4378 (2002) . Crossref, Medline, CAS, Google Scholar14 Runde V , De WT , Arnold R et al. ; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation . Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome . Bone Marrow Transplant. 21 , 255 – 261 (1998) . Crossref, Medline, CAS, Google Scholar15 Storb R . Reduced-intensity conditioning transplantation in myeloid malignancies . Curr. Opin. Oncol. 21 (Suppl. 1) , S3 – S5 (2009) . Crossref, Medline, Google Scholar16 Martino R , Iacobelli S , Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes . Blood 108 , 836 – 846 (2006) . Crossref, Medline, CAS, Google Scholar17 Scott BL , Sandmaier BM , Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis . Leukemia 20 , 128 – 135 (2006) . Crossref, Medline, CAS, Google Scholar18 Shimoni A , Hardan I , Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity . Leukemia 20 , 322 – 328 (2006) . Crossref, Medline, CAS, Google Scholar19 Shimoni A , Hardan I , Shem-Tov N , Yerushalmi R , Nagler A . Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up . Leukemia 24 , 1050 – 1052 (2010) . Crossref, Medline, CAS, Google Scholar20 Alyea EP , Kim HT , Ho V et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome . Biol. Blood Marrow Transplant. 12 , 1047 – 1055 (2006) . Crossref, Medline, Google Scholar21 Casper J , Knauf W , Blau I et al. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation . Ann. Hematol. 83 (Suppl. 1) , S70 – S71 (2004) . Medline, Google Scholar22 Hilgendorf I , Wolff D , Gromke T et al. Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome . Bone Marrow Transplant. 46 (4) , 502 – 509 (2010) . Medline, Google Scholar23 Nemecek ER , Guthrie KA , Sorror ML et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies . Biol. Blood Marrow Transplant. 17 (3) , 341 – 350 (2011) . Crossref, Medline, CAS, Google Scholar24 Ruutu T , Volin L , Beelen DW et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective Phase II trial . Haematologica 96 , 1344 – 1350 (2011) . Crossref, Medline, CAS, Google Scholar25 McClune BL , Weisdorf DJ , Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome . J. Clin. Oncol. 28 , 1878 – 1887 (2010) . Crossref, Medline, Google Scholar26 Lim Z , Brand R , Martino R et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia . J. Clin. Oncol. 28 , 405 – 411 (2010) . Crossref, Medline, Google Scholar27 Sorror ML , Sandmaier BM , Storer BE et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation . J. Clin. Oncol. 25 , 4246 – 4254 (2007) . Crossref, Medline, Google Scholar28 Sorror ML , Giralt S , Sandmaier BM et al. Hematopoietic Cell Transplantation Specific Comorbidity Index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences . Blood 110 , 4606 – 4613 (2007) . Crossref, Medline, CAS, Google Scholar29 Sorror ML , Sandmaier BM , Storer BE et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation . J. Clin. Oncol. 25 , 4246 – 4254 (2007) . Crossref, Medline, Google Scholar30 Armand P , Kim HT , DeAngelo DJ et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation . Biol. Blood Marrow Transplant. 13 , 655 – 664 (2007) . Crossref, Medline, CAS, Google Scholar31 Kroger N , Zabelina T , van BA et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis . Haematologica 96 (2) , 291 – 297 (2010) . Medline, Google Scholar32 Scott BL , Storer BE , Greene JE et al. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia . Biol. Blood Marrow Transplant. 13 , 345 – 354 (2007) . Crossref, Medline, Google Scholar33 Scott BL , Storer B , Loken MR et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome . Biol. Blood Marrow Transplant. 11 , 65 – 73 (2005) . Crossref, Medline, Google Scholar34 Nakai K , Kanda Y , Fukuhara S et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome . Leukemia 19 , 396 – 401 (2005) . Crossref, Medline, CAS, Google Scholar35 Schmid C , Schleuning M , Ledderose G , Tischer J , Kolb HJ . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome . J. Clin. Oncol. 23 , 5675 – 5687 (2005) . Crossref, Medline, Google Scholar36 Schmid C , Schleuning M , Hentrich M et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission . Bone Marrow Transplant. 41 , 721 – 727 (2008) . Crossref, Medline, CAS, Google Scholar37 Saure C , Schroeder T , Zohren F et al. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen . Biol Blood Marrow Transplant. 18 (3) , 466 – 472 (2012) . Crossref, Medline, Google Scholar38 Armand P , Kim HT , Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation . Blood 109 , 4586 – 4588 (2007) . Crossref, Medline, CAS, Google Scholar39 Platzbecker U , Bornhauser M , Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) . Biol. Blood Marrow Transplant. 14 , 1217 – 1225 (2008) . Crossref, Medline, CAS, Google Scholar40 Krishnamurthy P , Potter VT , Barber LD et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes . Biol. Blood Marrow Transplant. 19 (4) , 562 – 568 (2013) . Crossref, Medline, Google Scholar41 Schroeder T , Czibere A , Platzbecker U et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation . Leukemia. 27 (6) , 1229 – 1235 (2013) . Crossref, Medline, CAS, Google ScholarWebsite101 The European Society for Blood and Marrow Transplantation. www.ebmt.org Google ScholarFiguresReferencesRelatedDetails Novel Insights into Pathophysiology, Diagnostics and Treatment of Myelodysplastic SyndromesMetrics Downloaded 6 times History Published online 2 January 2014 Published in print January 2014 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2806769033 created "2018-06-13" @default.
• W2806769033 creator A5001433615 @default.
• W2806769033 date "2014-01-01" @default.
• W2806769033 modified "2023-10-18" @default.
• W2806769033 title "Hematopoietic stem cell transplantation in patients with myelodysplastic syndromes" @default.
• W2806769033 cites W1975550706 @default.
• W2806769033 cites W1983344261 @default.
• W2806769033 cites W1990481862 @default.
• W2806769033 cites W1992090010 @default.
• W2806769033 cites W1998345180 @default.
• W2806769033 cites W2004498221 @default.
• W2806769033 cites W2008586482 @default.
• W2806769033 cites W2010222433 @default.
• W2806769033 cites W2012548375 @default.
• W2806769033 cites W2021616418 @default.
• W2806769033 cites W2022978986 @default.
• W2806769033 cites W2030428868 @default.
• W2806769033 cites W2040041834 @default.
• W2806769033 cites W2046152217 @default.
• W2806769033 cites W2059192060 @default.
• W2806769033 cites W2068160300 @default.
• W2806769033 cites W2069566335 @default.
• W2806769033 cites W2071319321 @default.
• W2806769033 cites W2075324654 @default.
• W2806769033 cites W2090915775 @default.
• W2806769033 cites W2093403900 @default.
• W2806769033 cites W2097401497 @default.
• W2806769033 cites W2097534024 @default.
• W2806769033 cites W2099384791 @default.
• W2806769033 cites W2101570663 @default.
• W2806769033 cites W2103529718 @default.
• W2806769033 cites W2103628120 @default.
• W2806769033 cites W2104319503 @default.
• W2806769033 cites W2104604639 @default.
• W2806769033 cites W2117550229 @default.
• W2806769033 cites W2138523107 @default.
• W2806769033 cites W2147773887 @default.
• W2806769033 cites W2148968593 @default.
• W2806769033 cites W2169668771 @default.
• W2806769033 cites W2169770774 @default.
• W2806769033 cites W268116559 @default.
• W2806769033 doi "https://doi.org/10.2217/fmeb2013.13.94" @default.
• W2806769033 hasPublicationYear "2014" @default.
• W2806769033 type Work @default.
• W2806769033 sameAs 2806769033 @default.
• W2806769033 citedByCount "0" @default.
• W2806769033 crossrefType "other" @default.
• W2806769033 hasAuthorship W2806769033A5001433615 @default.
• W2806769033 hasConcept C109159458 @default.
• W2806769033 hasConcept C126322002 @default.
• W2806769033 hasConcept C203014093 @default.
• W2806769033 hasConcept C2777408962 @default.
• W2806769033 hasConcept C2780007613 @default.
• W2806769033 hasConcept C2780817109 @default.
• W2806769033 hasConcept C28328180 @default.
• W2806769033 hasConcept C2911091166 @default.
• W2806769033 hasConcept C2993713153 @default.
• W2806769033 hasConcept C502942594 @default.
• W2806769033 hasConcept C54355233 @default.
• W2806769033 hasConcept C71924100 @default.
• W2806769033 hasConcept C86803240 @default.
• W2806769033 hasConceptScore W2806769033C109159458 @default.
• W2806769033 hasConceptScore W2806769033C126322002 @default.
• W2806769033 hasConceptScore W2806769033C203014093 @default.
• W2806769033 hasConceptScore W2806769033C2777408962 @default.
• W2806769033 hasConceptScore W2806769033C2780007613 @default.
• W2806769033 hasConceptScore W2806769033C2780817109 @default.
• W2806769033 hasConceptScore W2806769033C28328180 @default.
• W2806769033 hasConceptScore W2806769033C2911091166 @default.
• W2806769033 hasConceptScore W2806769033C2993713153 @default.
• W2806769033 hasConceptScore W2806769033C502942594 @default.
• W2806769033 hasConceptScore W2806769033C54355233 @default.
• W2806769033 hasConceptScore W2806769033C71924100 @default.
• W2806769033 hasConceptScore W2806769033C86803240 @default.
• W2806769033 hasLocation W28067690331 @default.
• W2806769033 hasOpenAccess W2806769033 @default.
• W2806769033 hasPrimaryLocation W28067690331 @default.
• W2806769033 hasRelatedWork W1713072761 @default.
• W2806769033 hasRelatedWork W2033219189 @default.
• W2806769033 hasRelatedWork W2059431511 @default.
• W2806769033 hasRelatedWork W2136224237 @default.
• W2806769033 hasRelatedWork W2153588399 @default.
• W2806769033 hasRelatedWork W2386230525 @default.
• W2806769033 hasRelatedWork W2408811484 @default.
• W2806769033 hasRelatedWork W2428994244 @default.
• W2806769033 hasRelatedWork W2745596189 @default.
• W2806769033 hasRelatedWork W2164671137 @default.
• W2806769033 isParatext "false" @default.
• W2806769033 isRetracted "false" @default.
• W2806769033 magId "2806769033" @default.
• W2806769033 workType "other" @default.